source
- Moderna and Merck vaccine plus Keytruda cuts melanoma relapse risk by 42% in late-stage trialA late-stage adjuvant study of Moderna’s experimental melanoma vaccine, intismeran autogene, combined with Merck’s Keytruda showed a 42% reduction in the risk of relapse or death compared with Keyt…
- AbbVie’s HS drug lutikizumab meets Phase 3 goal but falls short of analyst expectationsAbbVie reported that its investigational IL‑1α/β inhibitor lutikizumab achieved the primary endpoint in the Phase 3 INTREPID study for hidradenitis suppurativa, a chronic inflammatory skin disease…